Privia Health exceeds 2025 targets with surge in profitability and cash flow

Privia Health Group (NASDAQ:PRVA) today announced fiscal year 2025 results that landed at or above the high end of its previously issued guidance, bolstered by strong provider implementation and a disciplined focus on value-based care.

The physician-enablement company posted total revenue of $2,122.8 million, representing a 22.3% increase over the prior year.

The company's profitability saw even sharper gains, with net income rising 59.3% to $22.9 million.

Adjusted EBITDA grew 38.8% year-over-year to $125.5 million, reflecting the scalability of Privia’s technology platform and clinical network as it expands across new and existing markets.

Privia Health enters 2026 with a robust balance sheet, ending the year with $479.7 million in cash and equivalents and maintaining a position with no debt.

Cash flow from operating activities was equally strong, climbing 49.5% to $163.4 million, providing the company with significant capital to fund organic growth and potential strategic initiatives.

Meanwhile, management issued a confident outlook for the 2026 fiscal year, highlighting the durability of its business model.

The company's guidance targets approximately 20% Adjusted EBITDA growth at the midpoint.

Furthermore, Privia expects a high efficiency in capital management, forecasting an 80% conversion of adjusted EBITDA to free cash flow.